Αποτελέσματα Αναζήτησης
Get the latest Eiger BioPharmaceuticals, Inc. (EIGR) stock news and headlines to help you in your trading and investing decisions.
4 Νοε 2021 · Eiger BioPharmaceuticals (EIGR) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.52 per share a year ago.
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.
A high-level overview of Eiger BioPharmaceuticals, Inc. (EIGRQ) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
27 Σεπ 2024 · Eiger InnoTherapeutics, Inc. completed the acquisition of Lonafarnib Antiviral Asset of Eiger BioPharmaceuticals, Inc. from Eiger BioPharmaceuticals, Inc. (OTCPK:EIGR.Q) for $5.2 million. Sep. 02 CI
Find the latest Eiger BioPharmaceuticals, Inc. (EIGR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Eiger BioPharmaceuticals stock analysis 2024. View EIGR current price, quote, financial & revenue summaries, forecast, earnings transcripts, and news.